

**Table 4. Results from Pietrantonio et al. meta-analysis<sup>28</sup>**

	<b>MSI-H</b>		<b>MSS</b>		<b>Interaction</b>
	Number of studies/ subgroups	Relative Effect (95% CI)	Number of studies	Relative Effect (95% CI)	
OS with anti-PD-1-based regimens	5	HR 0.34*** (0.21-0.54)	3	HR 0.85*** (0.71-1.00)	p = 0.003
OS with first line anti-PD-1 based regimens	3	HR 0.33* (0.19-0.57)	2	HR 0.82 (0.64-1.05)	p = 0.003
OS with anti-PD-1 monotherapy	3	HR 0.32*** (0.17-0.63)		NR	
OS with anti-PD-1-based chemoimmunotherapy	2	HR 0.35** (0.18-0.69)			
PFS with anti-PD-1 regimens, any line	3	HR 0.57* (0.33-0.97)		NR	
Response (ORR) with anti-PD-1 regimens, any line	3	RR 1.76* (1.10-2.83)		NR	

CI: confidence interval; HR: hazard ratio; MSI-H: microsatellite instability-high MSS: Microsatellite Stability; NR: not recorded; OS: overall survival; ORR: overall response rate; PFS: progression free survival; RR: response rate

\*p ≤ 0.05, \*\*p < 0.01, \*\*\*p < 0.001 compared to chemotherapy alone